IMI launches first antimicrobial resistance projects

Source: PharmaTimes Area: News The European Union's Innovative Medicines Initiative (IMI) has launched the first two projects under its research programme for antimicrobial resistance. The projects, launched under the New Drugs for Bad Bugs (ND4BB) programme are COMBACTE (Combating Bacterial Resistance in Europe) and TRANSLOCATION (Molecular basis of the bacterial cell wall permeability):   . The COMBACTE team plans to develop innovative trial designs that will facilitate the registration of novel antibacterial agents. It will also design and validate tests to support patient diagnoses, identify the most appropriate treatments and monitor patient responses.   . TRANSLOCATION will investigate new pathways for getting antibiotics into bacteria and preventing bacteria from expelling the drugs before they can take effect. It will work primarily on Gram-negative pathogens such as Escherichia coli and Klebsiella pneumoniae.
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news